Evaluating the costs of glycemic response with canagliflozin versus dapagliflozin and empagliflozin as add-on to metformin in patients with type 2 diabetes mellitus in the United Arab Emirates
| Autor: | Anders Troelsgaard Buchholt, A. Schubert, Vanessa Taieb, Ahmed Kamal, Antoine C El Khoury |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Blood Glucose
medicine.medical_specialty endocrine system diseases United Arab Emirates 030209 endocrinology & metabolism law.invention 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Glucosides Randomized controlled trial law Internal medicine medicine Empagliflozin Humans Hypoglycemic Agents In patient 030212 general & internal medicine Benzhydryl Compounds Canagliflozin Dapagliflozin Sodium-Glucose Transporter 2 Inhibitors Randomized Controlled Trials as Topic Glycemic business.industry nutritional and metabolic diseases Type 2 Diabetes Mellitus Bayes Theorem General Medicine Metformin Endocrinology Diabetes Mellitus Type 2 chemistry business medicine.drug |
| Zdroj: | Current Medical Research and Opinion. 33:1155-1163 |
| ISSN: | 1473-4877 0300-7995 |
| DOI: | 10.1080/03007995.2017.1310091 |
| Popis: | This study evaluates the cost of achieving glycemic control with three sodium glucose co-transporter 2 (SGLT2) inhibitors, canagliflozin, dapagliflozin, and empagliflozin, in patients with type 2 diabetes mellitus (T2DM) from the payer perspective in the United Arab Emirates (UAE).A systematic literature review identified randomized controlled trials of antihyperglycemic agents as add-on to metformin in patients with T2DM of 26 ± 4 weeks in duration, published by 10 September 2014. A Bayesian network-meta analysis (NMA) compared HbA1c changes with canagliflozin 100 and 300 mg versus dapagliflozin 10 mg and empagliflozin 10 and 25 mg. The cost associated with a 1% placebo-adjusted HbA1c reduction with each SGLT2 inhibitor as add-on to metformin was calculated based on NMA results and UAE drug costs.In the NMA, canagliflozin 100 and 300 mg were associated with HbA1c reductions (-0.67% and -0.79%) compared with dapagliflozin 10 mg (-0.41%) and empagliflozin 10 and 25 mg (-0.57% and -0.64%). Probabilities of canagliflozin 100 mg performing better were 79%, 60%, and 53% versus dapagliflozin 10 mg and empagliflozin 10 and 25 mg, respectively; probabilities for canagliflozin 300 mg performing better were 88%, 72%, and 65%, respectively. The cost per 1%-point reduction in HbA1c was projected to be lower with canagliflozin 100 and 300 mg ($448 and $422) compared with dapagliflozin 10 mg ($785) and empagliflozin 10 and 25 mg ($527 and $563).Canagliflozin may provide a greater glycemic response at a lower effective cost than dapagliflozin or empagliflozin for patients with T2DM inadequately controlled with metformin from the payer perspective in the UAE. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|